Expression profiles of six circulating microRNAs critical to atherosclerosis in patients with subclinical hypothyroidism: a clinical study.

CONTEXT Increasing evidence shows that subclinical hypothyroidism (SCH) is associated with atherosclerosis (ATH), but the association remains controversial. MicroRNAs (miRNAs) have been proved to be involved in atherosclerosis and dyslipidemia as gene regulators. OBJECTIVE The objective of the study was to determine the expression profiles of six serum miRNAs critical to atherosclerosis in SCH patients and reanalyze the association between atherosclerosis and SCH from a new perspective. OUTCOMES, DESIGN, AND PARTICIPANTS: MicroRNA profiling analysis was performed by real-time PCR in normal control subjects (NC; n = 22); patients with subclinical hypothyroidism alone (SCH; n = 20); SCH patients plus atherosclerosis (SCH+ATH; n = 21); and patients with atherosclerosis but without subclinical hypothyroidism (ATH; n = 22). RESULTS MiR-21-5p was up-regulated in SCH, SCH+ATH, and ATH groups than in the NC group. In addition, expression levels of miR-21-5p in SCH+ATH group were higher than in SCH alone and ATH alone groups, respectively. Both miR-125a-5p and miR-126-3p showed a decreased trend from NC to SCH and then to SCH+ATH or ATH subjects. MiR-221-3p and miR-222-3p were decreased in the SCH+ATH and ATH groups compared with either the NC or SCH groups. No differences were found in the levels of miR125a-5p, miR126-3p, miR221-3p, and miR222-3p between the ATH and SCH+ATH group. CONCLUSIONS MiR-21-5p showed the most specific expression patterns in all patients with subclinical hypothyroidism (SCH and SCH+ATH groups). Down-regulation of miR-125a-5p, miR-126-3p, miR-221-3p, and miR-222-3p may be a manifestation of atherosclerosis either in SCH+ATH or in ATH-alone patients. MiR-126-3p has the most specific expression patterns in all atherosclerosis patients (SCH+ATH and ATH groups).

[1]  Muneesh Tewari,et al.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). , 2010, Methods.

[2]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[3]  Velkoska Nakova Valentina,et al.  Subclinical hypothyroidism and risk to carotid atherosclerosis. , 2011, Arquivos brasileiros de endocrinologia e metabologia.

[4]  A. Dominiczak,et al.  2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.

[5]  Stefanie Dimmeler,et al.  Circulating MicroRNAs in Patients With Coronary Artery Disease , 2010, Circulation research.

[6]  M. Guan,et al.  Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[7]  Bairong Shen,et al.  Two Functional MicroRNA-126s Repress a Novel Target Gene p21-Activated Kinase 1 to Regulate Vascular Integrity in Zebrafish , 2011, Circulation research.

[8]  Yao‐Hua Song,et al.  MicroRNA-221 regulates high glucose-induced endothelial dysfunction. , 2009, Biochemical and biophysical research communications.

[9]  Yue Li,et al.  Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. , 2010, European heart journal.

[10]  Jan A Staessen,et al.  Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.

[11]  J. Franklyn,et al.  Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. , 2004, JAMA.

[12]  H. Biter,et al.  Prevalence of Subclinical Hypothyroidism among Patients with Acute Myocardial Infarction , 2011, ISRN endocrinology.

[13]  M. Rocco,et al.  Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. , 1996, JAMA.

[14]  Stefanie Dimmeler,et al.  Role of microRNAs in vascular diseases, inflammation, and angiogenesis. , 2008, Cardiovascular research.

[15]  M. Matsumoto,et al.  Ischemic stroke events and carotid atherosclerosis. Results of the Osaka Follow-up Study for Ultrasonographic Assessment of Carotid Atherosclerosis (the OSACA Study). , 1995, Stroke.

[16]  S. Fujii,et al.  Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol , 2012, Thrombosis Journal.

[17]  Y. Shoenfeld,et al.  Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus , 2003, Annals of the rheumatic diseases.

[18]  Michael J Pencina,et al.  Carotid-wall intima-media thickness and cardiovascular events. , 2011, The New England journal of medicine.

[19]  Ru-Fang Yeh,et al.  miR-126 regulates angiogenic signaling and vascular integrity. , 2008, Developmental cell.

[20]  R. Jorde,et al.  Serum lipid levels in relation to serum thyroid‐stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study , 2006, Journal of internal medicine.

[21]  Jiajun Zhao,et al.  Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. , 2012, The Journal of clinical endocrinology and metabolism.

[22]  E. Lyden,et al.  Pancreas transplantation improves vascular disease in patients with type 1 diabetes. , 2004, Diabetes care.

[23]  Francesca Orso,et al.  microRNA-222 Controls Neovascularization by Regulating Signal Transducer and Activator of Transcription 5A Expression , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[24]  Ting Chen,et al.  MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. , 2009, Cardiovascular research.

[25]  I. Shimomura,et al.  Maximum carotid intima-media thickness improves the prediction ability of coronary artery stenosis in type 2 diabetic patients without history of coronary artery disease. , 2012, Atherosclerosis.

[26]  C. Mathieu,et al.  Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. , 2012, The Journal of clinical endocrinology and metabolism.

[27]  E. Vittinghoff,et al.  Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. , 2005, Archives of internal medicine.

[28]  G. Ning,et al.  Differential microRNA expression in peripheral blood mononuclear cells from Graves' disease patients. , 2012, The Journal of clinical endocrinology and metabolism.

[29]  Joshua T. Mendell,et al.  MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1 , 2008, Proceedings of the National Academy of Sciences.

[30]  M. Vanderpump,et al.  The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. , 2010, The Journal of clinical endocrinology and metabolism.

[31]  L. Ghiadoni,et al.  Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. , 2003, The Journal of clinical endocrinology and metabolism.

[32]  Jian-yong Li,et al.  Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma , 2012, Annals of Hematology.

[33]  B. Hoogwerf,et al.  Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. , 2011, Thyroid : official journal of the American Thyroid Association.

[34]  P. Home,et al.  Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapy. , 2010, The Journal of clinical endocrinology and metabolism.

[35]  G. Ning,et al.  A novel role for thyroid‐stimulating hormone: Up‐regulation of hepatic 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme a reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate–responsive element binding protein pathway , 2010, Hepatology.

[36]  Lucian Calmac,et al.  Imaging Atherosclerosis by Carotid Intima-media Thickness in vivo: How to, Where and in Whom ? , 2012, Maedica.

[37]  John Quackenbush,et al.  Genesis: cluster analysis of microarray data , 2002, Bioinform..

[38]  Fabio Martelli,et al.  MicroRNA-210 as a Novel Therapy for Treatment of Ischemic Heart Disease , 2010, Circulation.

[39]  A. Baker.  MicroRNA 21 "shapes" vascular smooth muscle behavior through regulating tropomyosin 1. , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[40]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[41]  Mei Zhang,et al.  Mechanical Stretch Modulates MicroRNA 21 Expression, Participating in Proliferation and Apoptosis in Cultured Human Aortic Smooth Muscle Cells , 2012, PloS one.